Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

Iwama, Shintaro, De Remigis, Alessandra, Callahan, Margaret K., Slovin, Susan F., Wolchok, Jedd D., Caturegli, Patrizio · 2014 · Science Translational Medicine

Abstract

Hypophysitis is a chronic inflammation of the pituitary gland of unknown (primary forms) or recognizable (secondary forms) etiology, such as the use of ipilimumab in cancer immunotherapy. Ipilimumab, which blocks the T cell inhibitory molecule CTLA-4 (cytotoxic T lymphocyte antigen-4), induces hypophysitis in about 4% of patients through unknown mechanisms. We first established a model of secondary hypophysitis by repeated injections of a CTLA-4 blocking antibody into SJL/J or C57BL/6J mice, and showed that they developed lymphocytic infiltration of the pituitary gland and circulating pituitary antibodies. We next assessed the prevalence of pituitary antibodies in a cohort of 20 patients with advanced melanoma or prostate cancer, 7 with a clinical diagnosis of hypophysitis, before and after ipilimumab administration. Pituitary antibodies, negative at baseline, developed in the 7 patients with hypophysitis but not in the 13 without it; these antibodies predominantly recognized thyrotropin-, follicle-stimulating hormone-, and corticotropin-secreting cells. We then hypothesized that the injected CTLA-4 antibody could cause pituitary toxicity if bound to CTLA-4 antigen expressed "ectopically" on pituitary endocrine cells. Pituitary glands indeed expressed CTLA-4 at both RNA and protein levels, particularly in a subset of prolactin- and thyrotropin-secreting cells. Notably, these cells became the site of complement activation, featuring deposition of C3d and C4d components and an inflammatory cascade akin to that seen in type II hypersensitivity. In summary, the study offers a mechanism to explain the pituitary toxicity observed in patients receiving ipilimumab, and highlights the utility of measuring pituitary antibodies in this form of secondary hypophysitis.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3008002

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 64 references

Research works printed but not linked: 1

  1. 10.1172/JCI20401 · doi:10.1172/jci20401 · Paper page

Cited by

See all 715

Metadata

Authors
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P.
Affiliations
  • Johns Hopkins University (US)
  • Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA.
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Caturegli, Patrizio
Venue
Science Translational Medicine
Published
2014-04-02
Volume
6
Issue
230
Pages
230ra45-230ra45
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2085247907
Cited by
715
References
64
Citations by year
2026: 38 · 2025: 57 · 2024: 56 · 2023: 67 · 2022: 78 · 2021: 85 · 2020: 82 · 2019: 80 · 2018: 50 · 2017: 46 · 2016: 36 · 2015: 27 · 2014: 12
FWCI
19.45
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R21DK080351, DK 080351)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
hypophysitis, CTLA-4, ipilimumab, pituitary gland, immune checkpoint inhibitors, cancer immunotherapy toxicity, complement activation, type II hypersensitivity, lactotrophs, melanoma, prostate cancer
MeSH terms
Ipilimumab, Adult, Aged, Animals, Antibodies, Monoclonal, Autoantibodies, Complement System Proteins, Disease Models, Animal, Female, Flow Cytometry, Fluorescent Antibody Technique, Hematopoiesis, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Diseases, Pituitary Gland, Pituitary Neoplasms, Prolactin, Thyrotropin, Antibodies, Blocking, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. https://app.cochat.ai/papers/10.1126/scitranslmed.3008002
The paper
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014). Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3008002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.